Profits jump 20% at Irish arm of US biotech Regeneron

Regeneron's Irish arm saw a 20% profit increase to $4.91B in 2025, with revenues up 3% to $12.53B. The company paid $716.6M in taxes and $5.3B in dividends. Key drugs Dupixent, Eylea HD, and Libtayo showed strong sales growth. Manufacturing was briefly disrupted due to repairs.

Original reporting
Published Nov 18, 2026, 4:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 5:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Profits jump 20% at Irish arm of US biotech Regeneron — source image
Decision brief

The 30-second read

Med
01

Why it matters

The disclosed profit surge and dividend payouts provide fresh data for valuation models and may influence analyst forecasts.

02

Market read

First‑time release of Regeneron's Irish arm profit figures, indicating strong earnings momentum and cash generation.

03

What to watch

The $120 m Pillar Two tax increase and recent facility repairs could pressure margins despite higher revenue.

Relevance 8/10Novelty 8/10Timing: today

Background

Regeneron is a US‑listed biotech with a large manufacturing presence in Ireland, contributing the bulk of its global revenue.

Market effects

Biotech sector may benefit from demonstrated profitability of a major US multinational's Irish operations.

Irish corporate tax contributions rise, highlighting the country's role in pharma manufacturing.

Regeneron's strong earnings could lift sentiment for US biotech stocks globally.

Counterpoint

Profit growth may be offset by temporary production interruptions and higher tax liabilities, limiting upside.

Key entities

  • Regeneron Pharmaceuticals Inc.

    US biotech parent of the Irish arm.

Related articles

$REGNMed

European Commission approves flexible dosing for Regeneron’s Libtayo

Regeneron Pharmaceuticals (NASDAQ:REGN) received European Commission approval for a flexible dosing schedule for Libtayo (cemiplimab) across six cancer indications. The new regimen allows a 700 mg dose every six weeks after initial treatment, and reduced infusion times. The approval is based on clinical data and modeling. A U.S. review is ongoing, with a decision expected in March 2027.

$REGNMedAI 8/10

Regeneron’s POTS antibody curbs heart rate spikes, teeing up Phase 3 trial

Regeneron's Phase 2 trial for baloncibart (REGN7544) in POTS patients showed significant heart rate reduction at day 8, with the 450-mg dose maintaining benefits at day 29. The company plans to initiate Phase 3 trials in early 2025. According to Regeneron, the drug was generally well-tolerated, and improvements in physical functioning were observed in the higher dose group.